Cargando…

Blood‐derived product therapies for SARS‐CoV‐2 infection and long COVID

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is capable of large‐scale transmission and has caused the coronavirus disease 2019 (COVID‐19) pandemic. Patients with COVID‐19 may experience persistent long‐term health issues, known as long COVID. Both acute SARS‐CoV‐2 infection and long...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Junzheng, Yang, Huichuan, Yu, Ding, Yang, Xiaoming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651828/
https://www.ncbi.nlm.nih.gov/pubmed/38020714
http://dx.doi.org/10.1002/mco2.426
_version_ 1785147636799504384
author Wu, Junzheng
Yang, Huichuan
Yu, Ding
Yang, Xiaoming
author_facet Wu, Junzheng
Yang, Huichuan
Yu, Ding
Yang, Xiaoming
author_sort Wu, Junzheng
collection PubMed
description Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is capable of large‐scale transmission and has caused the coronavirus disease 2019 (COVID‐19) pandemic. Patients with COVID‐19 may experience persistent long‐term health issues, known as long COVID. Both acute SARS‐CoV‐2 infection and long COVID have resulted in persistent negative impacts on global public health. The effective application and development of blood‐derived products are important strategies to combat the serious damage caused by COVID‐19. Since the emergence of COVID‐19, various blood‐derived products that target or do not target SARS‐CoV‐2 have been investigated for therapeutic applications. SARS‐CoV‐2‐targeting blood‐derived products, including COVID‐19 convalescent plasma, COVID‐19 hyperimmune globulin, and recombinant anti‐SARS‐CoV‐2 neutralizing immunoglobulin G, are virus‐targeting and can provide immediate control of viral infection in the short term. Non‐SARS‐CoV‐2‐targeting blood‐derived products, including intravenous immunoglobulin and human serum albumin exhibit anti‐inflammatory, immunomodulatory, antioxidant, and anticoagulatory properties. Rational use of these products can be beneficial to patients with SARS‐CoV‐2 infection or long COVID. With evidence accumulated since the pandemic began, we here summarize the progress of blood‐derived product therapies for COVID‐19, discuss the effective methods and scenarios regarding these therapies, and provide guidance and suggestions for clinical treatment.
format Online
Article
Text
id pubmed-10651828
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-106518282023-11-15 Blood‐derived product therapies for SARS‐CoV‐2 infection and long COVID Wu, Junzheng Yang, Huichuan Yu, Ding Yang, Xiaoming MedComm (2020) Reviews Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is capable of large‐scale transmission and has caused the coronavirus disease 2019 (COVID‐19) pandemic. Patients with COVID‐19 may experience persistent long‐term health issues, known as long COVID. Both acute SARS‐CoV‐2 infection and long COVID have resulted in persistent negative impacts on global public health. The effective application and development of blood‐derived products are important strategies to combat the serious damage caused by COVID‐19. Since the emergence of COVID‐19, various blood‐derived products that target or do not target SARS‐CoV‐2 have been investigated for therapeutic applications. SARS‐CoV‐2‐targeting blood‐derived products, including COVID‐19 convalescent plasma, COVID‐19 hyperimmune globulin, and recombinant anti‐SARS‐CoV‐2 neutralizing immunoglobulin G, are virus‐targeting and can provide immediate control of viral infection in the short term. Non‐SARS‐CoV‐2‐targeting blood‐derived products, including intravenous immunoglobulin and human serum albumin exhibit anti‐inflammatory, immunomodulatory, antioxidant, and anticoagulatory properties. Rational use of these products can be beneficial to patients with SARS‐CoV‐2 infection or long COVID. With evidence accumulated since the pandemic began, we here summarize the progress of blood‐derived product therapies for COVID‐19, discuss the effective methods and scenarios regarding these therapies, and provide guidance and suggestions for clinical treatment. John Wiley and Sons Inc. 2023-11-15 /pmc/articles/PMC10651828/ /pubmed/38020714 http://dx.doi.org/10.1002/mco2.426 Text en © 2023 The Authors. MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Reviews
Wu, Junzheng
Yang, Huichuan
Yu, Ding
Yang, Xiaoming
Blood‐derived product therapies for SARS‐CoV‐2 infection and long COVID
title Blood‐derived product therapies for SARS‐CoV‐2 infection and long COVID
title_full Blood‐derived product therapies for SARS‐CoV‐2 infection and long COVID
title_fullStr Blood‐derived product therapies for SARS‐CoV‐2 infection and long COVID
title_full_unstemmed Blood‐derived product therapies for SARS‐CoV‐2 infection and long COVID
title_short Blood‐derived product therapies for SARS‐CoV‐2 infection and long COVID
title_sort blood‐derived product therapies for sars‐cov‐2 infection and long covid
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651828/
https://www.ncbi.nlm.nih.gov/pubmed/38020714
http://dx.doi.org/10.1002/mco2.426
work_keys_str_mv AT wujunzheng bloodderivedproducttherapiesforsarscov2infectionandlongcovid
AT yanghuichuan bloodderivedproducttherapiesforsarscov2infectionandlongcovid
AT yuding bloodderivedproducttherapiesforsarscov2infectionandlongcovid
AT yangxiaoming bloodderivedproducttherapiesforsarscov2infectionandlongcovid